Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Pneumococcal Vaccines | 3 | 2019 | 571 | 1.11 | Why? |
| Herpes Zoster Vaccine | 1 | 2019 | 112 | 0.69 | Why? |
| Adenovirus Infections, Human | 1 | 2018 | 145 | 0.64 | Why? |
| Adenoviruses, Human | 1 | 2018 | 195 | 0.63 | Why? |
| Pneumococcal Infections | 2 | 2019 | 562 | 0.60 | Why? |
| Pneumonia, Pneumococcal | 1 | 2018 | 251 | 0.58 | Why? |
| Republic of Korea | 17 | 2021 | 5858 | 0.49 | Why? |
| Cost-Benefit Analysis | 2 | 2019 | 2259 | 0.45 | Why? |
| Mass Vaccination | 1 | 2018 | 1101 | 0.35 | Why? |
| Military Personnel | 1 | 2018 | 1097 | 0.35 | Why? |
| Streptococcus pneumoniae | 3 | 2019 | 827 | 0.29 | Why? |
| Fever | 2 | 2019 | 7795 | 0.23 | Why? |
| Influenza, Human | 7 | 2020 | 10779 | 0.21 | Why? |
| Respiratory Tract Infections | 2 | 2018 | 6817 | 0.20 | Why? |
| Arthralgia | 1 | 2021 | 173 | 0.20 | Why? |
| Diphtheria-Tetanus Vaccine | 1 | 2018 | 16 | 0.19 | Why? |
| Influenza A Virus, H3N2 Subtype | 3 | 2019 | 572 | 0.19 | Why? |
| Vaccines, Conjugate | 2 | 2018 | 328 | 0.19 | Why? |
| Cyclopentanes | 1 | 2018 | 55 | 0.19 | Why? |
| Tetanus | 1 | 2018 | 61 | 0.18 | Why? |
| Herpes Zoster | 2 | 2017 | 331 | 0.18 | Why? |
| Enzyme-Linked Immunospot Assay | 1 | 2019 | 325 | 0.18 | Why? |
| Diphtheria | 1 | 2018 | 74 | 0.18 | Why? |
| Molecular Typing | 1 | 2018 | 280 | 0.16 | Why? |
| Delphi Technique | 1 | 2021 | 1257 | 0.16 | Why? |
| Geography, Medical | 1 | 2019 | 537 | 0.16 | Why? |
| Hemagglutinins | 1 | 2017 | 143 | 0.16 | Why? |
| Work Schedule Tolerance | 1 | 2017 | 158 | 0.15 | Why? |
| Myalgia | 1 | 2021 | 1015 | 0.15 | Why? |
| Vaccination | 5 | 2021 | 19050 | 0.15 | Why? |
| Quality-Adjusted Life Years | 1 | 2018 | 511 | 0.15 | Why? |
| Severe Dengue | 1 | 2017 | 135 | 0.14 | Why? |
| Absenteeism | 1 | 2017 | 287 | 0.14 | Why? |
| Neuraminidase | 1 | 2017 | 289 | 0.14 | Why? |
| Hemagglutination Inhibition Tests | 3 | 2019 | 191 | 0.13 | Why? |
| Guanidines | 1 | 2018 | 499 | 0.13 | Why? |
| Vaccines, Attenuated | 1 | 2019 | 952 | 0.13 | Why? |
| Healthy Volunteers | 1 | 2019 | 1444 | 0.13 | Why? |
| Molecular Epidemiology | 1 | 2018 | 1638 | 0.12 | Why? |
| Propensity Score | 1 | 2020 | 2690 | 0.12 | Why? |
| Vaccines, Inactivated | 1 | 2019 | 1562 | 0.11 | Why? |
| Delayed Diagnosis | 1 | 2020 | 1529 | 0.10 | Why? |
| Resource Allocation | 1 | 2021 | 1771 | 0.10 | Why? |
| Immunity, Cellular | 2 | 2021 | 3614 | 0.10 | Why? |
| Vaccination Coverage | 1 | 2019 | 1249 | 0.10 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 1261 | 0.09 | Why? |
| Lymphohistiocytosis, Hemophagocytic | 1 | 2017 | 800 | 0.09 | Why? |
| Immunity, Humoral | 2 | 2021 | 4849 | 0.09 | Why? |
| Double-Blind Method | 1 | 2019 | 5988 | 0.09 | Why? |
| Incidence | 3 | 2019 | 25622 | 0.08 | Why? |
| Influenza A Virus, H1N1 Subtype | 2 | 2019 | 2984 | 0.08 | Why? |
| Adult | 18 | 2021 | 244371 | 0.08 | Why? |
| Public Health | 3 | 2021 | 16359 | 0.08 | Why? |
| Odds Ratio | 1 | 2018 | 5861 | 0.08 | Why? |
| Immunization Programs | 1 | 2019 | 2006 | 0.08 | Why? |
| Middle Aged | 18 | 2021 | 270681 | 0.08 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.08 | Why? |
| Female | 20 | 2021 | 380317 | 0.08 | Why? |
| Young Adult | 8 | 2021 | 93724 | 0.08 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.08 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.07 | Why? |
| Aged | 14 | 2021 | 215776 | 0.07 | Why? |
| Phylogeny | 3 | 2018 | 13341 | 0.07 | Why? |
| Hospitals, Teaching | 1 | 2013 | 1609 | 0.07 | Why? |
| Male | 17 | 2021 | 367725 | 0.07 | Why? |
| Humans | 30 | 2021 | 930598 | 0.07 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2010 | 952 | 0.07 | Why? |
| Asymptomatic Infections | 2 | 2020 | 7218 | 0.07 | Why? |
| Saliva | 1 | 2020 | 4679 | 0.06 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 7868 | 0.06 | Why? |
| Immunogenicity, Vaccine | 1 | 2018 | 4624 | 0.06 | Why? |
| Evolution, Molecular | 1 | 2017 | 3691 | 0.06 | Why? |
| Polymerase Chain Reaction | 1 | 2018 | 6740 | 0.06 | Why? |
| Influenza Vaccines | 1 | 2019 | 2941 | 0.06 | Why? |
| Immunocompromised Host | 1 | 2019 | 5150 | 0.06 | Why? |
| Socioeconomic Factors | 1 | 2019 | 8495 | 0.06 | Why? |
| Joints | 1 | 2021 | 97 | 0.05 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.05 | Why? |
| Follow-Up Studies | 1 | 2019 | 17020 | 0.05 | Why? |
| Seasons | 3 | 2018 | 4071 | 0.05 | Why? |
| Seoul | 1 | 2020 | 206 | 0.05 | Why? |
| Coronavirus Infections | 8 | 2021 | 253789 | 0.05 | Why? |
| Virus Shedding | 3 | 2021 | 5834 | 0.05 | Why? |
| Viral Load | 1 | 2020 | 15850 | 0.05 | Why? |
| Acids, Carbocyclic | 1 | 2018 | 27 | 0.05 | Why? |
| Nasopharyngeal Neoplasms | 1 | 2019 | 64 | 0.05 | Why? |
| Pneumonia | 1 | 2019 | 5652 | 0.05 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2021 | 8843 | 0.05 | Why? |
| Antibodies, Viral | 3 | 2021 | 51949 | 0.05 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.04 | Why? |
| Cross Infection | 1 | 2020 | 8675 | 0.04 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 9335 | 0.04 | Why? |
| Anti-HIV Agents | 1 | 2010 | 2209 | 0.04 | Why? |
| Cytokines | 1 | 2019 | 15010 | 0.04 | Why? |
| Prospective Studies | 5 | 2021 | 43301 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Antiviral Agents | 2 | 2020 | 41703 | 0.04 | Why? |
| Marketing | 1 | 2018 | 195 | 0.04 | Why? |
| Population Surveillance | 1 | 2013 | 4967 | 0.04 | Why? |
| Betacoronavirus | 7 | 2020 | 204454 | 0.04 | Why? |
| Outpatients | 2 | 2020 | 3417 | 0.04 | Why? |
| Virus Diseases | 1 | 2013 | 3779 | 0.04 | Why? |
| Single-Blind Method | 1 | 2019 | 1283 | 0.04 | Why? |
| Infant, Newborn | 3 | 2021 | 23105 | 0.04 | Why? |
| Treatment Outcome | 2 | 2021 | 51732 | 0.04 | Why? |
| Colonic Neoplasms | 1 | 2019 | 295 | 0.04 | Why? |
| Health Personnel | 2 | 2021 | 29646 | 0.03 | Why? |
| Communicable Disease Control | 2 | 2020 | 29620 | 0.03 | Why? |
| Infant | 3 | 2021 | 30274 | 0.03 | Why? |
| Statistics, Nonparametric | 1 | 2017 | 1008 | 0.03 | Why? |
| Efficiency | 1 | 2017 | 420 | 0.03 | Why? |
| Influenza B virus | 1 | 2019 | 815 | 0.03 | Why? |
| Disability Evaluation | 1 | 2017 | 671 | 0.03 | Why? |
| Antipsychotic Agents | 1 | 2021 | 887 | 0.03 | Why? |
| Child, Preschool | 3 | 2021 | 36283 | 0.03 | Why? |
| North America | 1 | 2017 | 1400 | 0.03 | Why? |
| Antineoplastic Agents, Immunological | 1 | 2019 | 830 | 0.03 | Why? |
| Pneumonia, Bacterial | 1 | 2019 | 843 | 0.03 | Why? |
| Latin America | 1 | 2017 | 1721 | 0.03 | Why? |
| Contact Tracing | 2 | 2021 | 8448 | 0.03 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.03 | Why? |
| Adolescent | 4 | 2021 | 86841 | 0.03 | Why? |
| Asia | 1 | 2017 | 2399 | 0.02 | Why? |
| Pain | 1 | 2017 | 1084 | 0.02 | Why? |
| Activities of Daily Living | 1 | 2017 | 1530 | 0.02 | Why? |
| Early Diagnosis | 1 | 2017 | 2443 | 0.02 | Why? |
| Hospitals, University | 1 | 2020 | 4173 | 0.02 | Why? |
| Child | 3 | 2021 | 70012 | 0.02 | Why? |
| Cohort Studies | 3 | 2017 | 36005 | 0.02 | Why? |
| Decision Making | 1 | 2021 | 3132 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2020 | 7268 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2021 | 9893 | 0.02 | Why? |
| Vulnerable Populations | 1 | 2020 | 3099 | 0.02 | Why? |
| Dyspnea | 1 | 2019 | 3847 | 0.02 | Why? |
| Cough | 1 | 2019 | 4891 | 0.02 | Why? |
| Multiplex Polymerase Chain Reaction | 1 | 2013 | 1439 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2020 | 10017 | 0.02 | Why? |
| HIV Infections | 1 | 2010 | 11620 | 0.02 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.02 | Why? |
| T-Lymphocytes | 1 | 2021 | 6670 | 0.02 | Why? |
| Tomography, X-Ray Computed | 2 | 2021 | 25144 | 0.02 | Why? |
| HIV | 1 | 2010 | 1116 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2017 | 7220 | 0.01 | Why? |
| Disease Outbreaks | 2 | 2020 | 27595 | 0.01 | Why? |
| Breast Neoplasms | 1 | 2019 | 3633 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2021 | 11041 | 0.01 | Why? |
| Hospitals | 1 | 2020 | 11793 | 0.01 | Why? |
| RNA, Viral | 2 | 2018 | 32276 | 0.01 | Why? |
| Antigens, Viral | 1 | 2017 | 6298 | 0.01 | Why? |
| Adrenal Cortex Hormones | 1 | 2017 | 6537 | 0.01 | Why? |
| Retrospective Studies | 2 | 2020 | 105322 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.01 | Why? |
| Time Factors | 1 | 2018 | 31397 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2021 | 43792 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2020 | 53120 | 0.01 | Why? |
| Risk Factors | 1 | 2021 | 71621 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2017 | 48226 | 0.01 | Why? |
Cheong's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(160)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(89)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_